Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ698MR)

This product GTTS-WQ698MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ698MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1468MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ13883MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ4719MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ12270MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ5605MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ1265MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ5751MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ3043MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW